Author:
Nistala Ravi,Whaley-Connell Adam
Reference69 articles.
1. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis, 2007. 49(2 Suppl 2): S12–154.
2. Epstein, M. and V.M. Campese. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis, 2005. 45(1): 2–14.
3. Whaley-Connell, A., J. Habibi, R. Nistala, et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension, 2008. 51(2): 474–80.
4. Wassmann, S., U. Laufs, K. Muller, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol, 2002. 22(2): 300–5.
5. Romayne Kurukulasuriya, L., G. Athappan, G. Saab, et al. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence. Ther Adv Cardiovasc Dis, 2007. 1(1): 49–59.